Nouscom today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting. NOUS-209, Nouscom’s lead product, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens. It is being investigated in…
从这篇文章中可以得到什么：
- The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
- NOUS-209, Nouscom’s lead product, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
- eTurboNews 文章仅供订阅者使用。
